Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
Journal of Korean Medical Science
; : 1160-1163, 2016.
Article
en En
| WPRIM
| ID: wpr-13343
Biblioteca responsable:
WPRO
ABSTRACT
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities, and poor functional status. Thus, treatment of elderly patients with relapsed or refractory PTCL remains a challenge for clinicians. A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib. Weekly pralatrexate and bortezomib were administered intravenously for 3 weeks in a 4-week cycle. Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles. Only 1 patient experienced grade 3 thrombocytopenia and neutropenia. Two patients suffered from grade 3 mucositis. Combination therapy with pralatrexate and bortezomib may be used as a salvage therapy for relapsed or refractory PTCL in the elderly with a favorable safety profile.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Esquema de Medicación
/
Linfoma de Células T Periférico
/
Quimioterapia Combinada
/
Bortezomib
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
/
Aminopterina
/
Recurrencia Local de Neoplasia
/
Neutropenia
/
Antineoplásicos
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Journal of Korean Medical Science
Año:
2016
Tipo del documento:
Article